This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.
In this video, Rachel A. Freedman, MD, MPH, of the Dana-Farber Cancer Institute, discusses results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.
Freedman presented the results of the study (abstract 1005) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
Lasofoxifene Combo Yields Meaningful Activity in ER+/HER2– Breast Cancer
June 6th 2023The anti-tumor activity of lasofoxifene plus abemaciclib does not appear to be compromised by co-occurring alterations that confer resistance among patients with estrogen receptor–positive HER2-negative breast cancer.
Sacituzumab Govitecan Yields Enduring Survival in HR+, HER2– Breast Cancer
June 5th 2023Additionally, treatment with sacituzumab govitecan-hziy may result in a prolonged overall response rate and clinical benefit rate vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.